Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9595)	4/11/1999 8:32:00 PM
From: Robert K.	Respond to of 17367

Cacaito, you better read those "examples" 1 thru 4 in that patent. Nothing new is incorrect. Glascow fifteens are knocking on heavens door. If YOU were the doc what would you assess. I dont have those skills. Would really like your opinion if you should look again. Also>I have been kinda following intrabiotics for a few years. Pigs I think. Same bpi principal but look at their anemic targets. George>"Polymorphonuclear neutrophil (PMNL) activation enhances microbial clearance but also contributes to the vascular damage and multiorgan failure associated with severe meningococcal sepsis. " This is important. Bpi impedes PMNL activation. Keep in mind> vascular damage and multi-organ failure re sepsis. All disclaimers always apply to all my notes.